INBP's Revenue Highly Concentrated, Faces Stiff Competition

TL;DR

**INBP is a high-risk bet due to its dangerously concentrated customer base and fierce competition in a heavily regulated market.**

AI Summary

INTEGRATED BIOPHARMA INC (INBP) reported a significant concentration of consolidated net sales, with approximately 84% in fiscal year 2025 and 90% in fiscal year 2024 derived from just two customers: Life Extension Quality Supplements and Vitamins, Inc. and Herbalife Nutrition LTD. These two customers accounted for 62% and 26% of the Contract Manufacturing Segment's net sales in 2025, respectively, and 71% and 23% in 2024. The company's aggregate market value of voting and non-voting common equity held by non-affiliates was $3,111,877 as of December 31, 2024. As of September 23, 2025, there were 31,059,610 shares of Common Stock outstanding. INBP operates primarily in manufacturing, distributing, marketing, and sales of vitamins, nutritional supplements, and herbal products, with its Contract Manufacturing segment being the primary revenue driver. The company faces high competition from larger entities with greater financial resources and is subject to extensive government regulations from agencies like the FDA and FTC, which could necessitate changes in business practices or product offerings.

Why It Matters

INBP's extreme customer concentration, with 84% of 2025 revenue from just two clients, poses a substantial risk to investors; the loss of either Life Extension or Herbalife could severely impact financial stability. This dependency also limits INBP's negotiating power and market diversification compared to larger, more established competitors in the nutraceutical space. For employees, this concentration could mean job insecurity if a major client relationship sours, while customers might see less innovation if INBP's focus remains on a few large contracts. The broader market should note INBP's vulnerability in a highly competitive and regulated industry, highlighting the challenges smaller players face against pharmaceutical giants and well-funded direct marketers.

Risk Assessment

Risk Level: high — The risk level is high due to extreme customer concentration, with 84% of consolidated net sales in fiscal year 2025 and 90% in fiscal year 2024 coming from just two customers, Life Extension and Herbalife. The loss of either customer, particularly given the December 31, 2025 termination date for the Herbalife development and supply agreements, could have a significant adverse impact on INBP's financial condition and results of operations.

Analyst Insight

Investors should avoid INBP given its precarious customer concentration and the looming expiration of key supply agreements. The company's small market capitalization of $3,111,877 and lack of diversified revenue streams make it highly susceptible to market shifts and client churn.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $3,111,877 — Aggregate market value of common equity held by non-affiliates (as of December 31, 2024, indicating a small market capitalization)
• 84% — Consolidated net sales from two major customers (in fiscal year 2025, highlighting extreme customer concentration)
• 90% — Consolidated net sales from two major customers (in fiscal year 2024, indicating consistent high concentration)
• 62% — Contract Manufacturing Segment net sales from Life Extension (in fiscal year 2025, showing significant reliance on one customer)
• 26% — Contract Manufacturing Segment net sales from Herbalife (in fiscal year 2025, showing significant reliance on a second customer)
• 31,059,610 — Shares of Common Stock outstanding (as of September 23, 2025)
• December 31, 2025 — Termination date of Herbalife development and supply agreements (poses a near-term risk to a significant revenue stream)

Key Players & Entities

• INTEGRATED BIOPHARMA INC (company) — registrant
• Life Extension Quality Supplements and Vitamins, Inc. (company) — major customer, 62% of Contract Manufacturing net sales in 2025
• Herbalife Nutrition LTD (company) — major customer, 26% of Contract Manufacturing net sales in 2025
• Manhattan Drug Company, Inc. (company) — operates Contract Manufacturing segment
• FDA (regulator) — regulates manufacturing, labeling, and sale of products
• FTC (regulator) — regulates marketing practices and advertising
• DSM Nutritional Products LLC (company) — principal supplier for Other Business Lines Segment
• Herbalife International of America, Inc. (company) — subsidiary of Herbalife, party to development and supply agreement
• Herbalife International of Luxembourg S..R.L (company) — subsidiary of Herbalife, party to development and supply agreement
• Chem International, Inc. (company) — distributor of raw materials and holding entity

FAQ

Risk Factors

• Customer Concentration Risk [high — financial]: Approximately 84% of consolidated net sales in fiscal year 2025 and 90% in fiscal year 2024 were derived from just two customers, Life Extension and Herbalife. The loss of either of these customers could have a significant adverse impact on the company's financial condition and results of operations.
• Supply Chain Disruptions [medium — operational]: Geo-political events and general transportation issues are causing delays in receiving raw materials and meeting delivery dates. While not yet significantly impacting margins, inflation, tariffs, and labor markets are causing a slight negative impact.
• Regulatory Compliance Costs [high — regulatory]: The company is subject to extensive regulation by agencies like the FDA and FTC. Complying with new and existing regulations, both domestic and international, could significantly increase costs and adversely affect financial results, potentially requiring product reformulation or removal.

Industry Context

Integrated BioPharma operates in the competitive vitamins, nutritional supplements, and herbal products market. The industry is characterized by a high degree of competition, including larger entities with greater financial resources. Companies in this sector are also subject to extensive government regulations concerning product safety, labeling, and marketing.

Regulatory Implications

The company faces significant regulatory oversight from agencies like the FDA and FTC. Compliance with these regulations is critical and can lead to increased costs, potential delays in product launches, or even necessitate product recalls, directly impacting financial performance and operations.

What Investors Should Do

1. Monitor customer concentration closely.
2. Assess the impact of Herbalife agreement termination.
3. Evaluate the company's strategy for diversification.
4. Scrutinize regulatory compliance and potential costs.

Key Dates

• 2024-12-31: Aggregate market value of common equity held by non-affiliates reported — Indicates a very small market capitalization of $3,111,877.
• 2025-06-30: Fiscal year end — Reporting period for 84% consolidated net sales from two major customers and 62% Contract Manufacturing Segment net sales from Life Extension.
• 2024-06-30: Fiscal year end — Reporting period for 90% consolidated net sales from two major customers and 71% Contract Manufacturing Segment net sales from Life Extension.
• 2025-09-23: Shares of Common Stock outstanding reported — 31,059,610 shares outstanding as of this date.

Glossary

Contract Manufacturing Segment

A business segment focused on manufacturing vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. (This segment is the primary revenue driver for the company, with significant concentration from two major customers.)

Other Business Lines

Includes warehousing and fulfillment services, distribution of raw materials, and inactive subsidiaries. (While not the primary revenue driver, this segment also shows customer concentration issues with other significant clients.)

FDA

Food and Drug Administration, a U.S. federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, food, cosmetics, and products that emit radiation. (The company's products are subject to FDA regulations, which can impact product introduction, reformulation, and potentially require product removal.)

FTC

Federal Trade Commission, a U.S. federal agency responsible for consumer protection and the prevention of anticompetitive business practices. (The company's advertising and sales practices are subject to FTC regulation, which could necessitate changes in business practices.)

Year-Over-Year Comparison

The provided 10-K focuses on fiscal years 2025 and 2024. Key metrics like revenue growth, margin changes, and specific financial figures for comparison to a prior year (e.g., 2023) are not detailed in the provided text. However, the extreme customer concentration (84% in 2025 vs. 90% in 2024) remains a consistent and significant risk factor, indicating no improvement in diversification.

Filing Documents

• inbp20250630_10k.htm (10-K) — 1269KB
• ex_860011.htm (EX-19) — 16KB
• ex_834958.htm (EX-21) — 8KB
• ex_862773.htm (EX-23.1) — 2KB
• ex_862774.htm (EX-23.2) — 2KB
• ex_834954.htm (EX-31.1) — 20KB
• ex_834955.htm (EX-31.2) — 17KB
• ex_834956.htm (EX-32.1) — 9KB
• ex_834957.htm (EX-32.2) — 7KB
• 0001437749-25-029711.txt ( ) — 6875KB
• inbp-20250630.xsd (EX-101.SCH) — 58KB
• inbp-20250630_cal.xml (EX-101.CAL) — 43KB
• inbp-20250630_def.xml (EX-101.DEF) — 403KB
• inbp-20250630_lab.xml (EX-101.LAB) — 368KB
• inbp-20250630_pre.xml (EX-101.PRE) — 435KB
• inbp20250630_10k_htm.xml (XML) — 1143KB

Risk Factors

Risk Factors 9 Item 1B. Unresolved Staff Comments 14 Item 1C. Cybersecurity 14 Item 2.

Properties

Properties 14 Item 3.

Legal Proceedings

Legal Proceedings 15 Item 4. Mine Safety Disclosure 15 Part II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 15 Item 6. [Reserved] 16 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 24 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 24 Item 9A.

Controls and Procedures

Controls and Procedures 24 Item 9B. Other Information 25 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 25 Part III Item 10. Directors, Executive Officers and Corporate Governance 25 Item 11.

Executive Compensation

Executive Compensation 25 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 25 Item 13. Certain Relationships and Related Transactions and Director Independence 25 Item 14. Principal Accountant Fees and Services 25 Part IV Item 15. Exhibits and Financial Statement Schedules 26 Item 16. Form10-K Summary 29

Signatures

Signatures 55 -2- CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this Annual Report on Form 10-K may constitute "forward-looking" statements as defined in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Private Securities Litigation Reform Act of 1995 (the "PSLRA") or in releases made by the Securities and Exchange Commission ("SEC"), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Integrated BioPharma, Inc. and its subsidiaries (collectively, the "Company") or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by the Company; changes in industry capacity; pressure on prices from competition or from purchasers of the Company's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to the Company; availability of qualified personnel; the loss of any significant customers or suppliers; inflation (including those caused by tariffs) and tightened labor markets; and other factors both referenced and not referenced in this Annual Report. Statements that are not historical fact are forward-looking statements. Forward looking-statements can be identified by, among other things, the use of forward-looking language, such as the words "plan", "believe", "expect", "anticipa

Description of Business

Item 1. Description of Business General Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the "Company"), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company's customers are located primarily in the United States and Luxembourg. The Company was originally incorporated in the state of Delaware on August 31, 1995 under the name Chem International, Inc., on December 5, 2000, changed its name to Integrated Health Technologies, Inc. and, on January 29, 2003, changed its name to Integrated BioPharma, Inc. The Company restated its certificate of incorporation in Delaware in June 2006. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors. The Company's business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. ("MDC"), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Business Lines which includes the operations of (i) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services, (ii) Chem International, Inc. ("Chem"), a distributor of certain raw materials for DSM Nutritional Products LLC and the holding entity of the Company and (iii) all other inactive subsidiaries of the Company. Significant Revenues from Major Customers In the fiscal years ended June 30, 2025 and 2024, a significant portion of our consolidated net sales, approximately 84% and 90%, respectively, were concentrated among two customers, Life Extension Quality Supplements and Vitamins, Inc. ("Life Extension") and Herbalife Nutrition LTD ("Herbalife"), both customers in our Contract Manufacturing Segment. Life Extension and Herbalife represented approximately 62% and 26% and 71% and 23%, respectively, of our Contract Manufac

Risk Factors

Item 1A. Risk Factors Please carefully consider the following risk factors which could materially adversely affect our business, financial condition, operating results and cash flows. The risk factors described below are not the only ones we face. Risks and uncertainties not known to us currently, or that we currently deem immaterial, also may materially adversely affect our business, financial condition, operating results and cash flows. Our revenue could decline significantly if we lose one or more of our most significant customers, which could have a significant adverse impact on us. A significant portion of our revenues are concentrated among six customers, Life Extension and Herbalife (customers in our Contract Manufacturing Segment) and Trusted Influencers Inc. (Hotpack Global, Inc. in 2024), Thermosource Tooling and Manufacturing, Life Technologies, Inc. and Eastern Drayage (customers of our Other Business Lines Segment). In the fiscal years ended June 30, 2025 and 2024, approximately 84% and 90% of our consolidated net sales, respectively, were derived from the two major customers in our Contract Manufacturing Segment. The loss of any of these customers could have a significant adverse impact on our financial condition and results of operations. Supply chain disruptions resulting from geo-political events could have an impact on our financial results and ability to timely ship products to our customers. These issues first arose as result of the COVID-19 pandemic and other geo-political events. Transportation, in general, continues to be an issue in the delay of receiving raw materials and our ability to meet promised delivery dates to our customers in the Contract Manufacturing Segment. While we haven't, to date, seen a significant negative impact in our margins resulting from the geo-political events, we are experiencing a slight negative impact on our margins due to inflation, including tariffs, delays in shipments and tightened labor markets. C

View Full Filing

View this 10-K filing on SEC EDGAR